Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors

$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $ALGS alert in real time by email

SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed James Scopa, J.D., MBA, to the Company's board of directors.

"We are thrilled to add someone of Jim's experience and accomplishments to Aligos' board, as the company continues its arc from its earliest, private, preclinical phase to growing into its role as an established clinical-stage public biopharma company," said Aligos Chief Executive Officer Lawrence Blatt, Ph.D., MBA. "Aligos will look to Jim for strategic counsel as the company approaches mid-stage clinical trials in chronic hepatitis B. We believe that Jim, with his extensive industry experience and his service as a director for numerous companies, will make a welcome addition to our board."

Mr. Scopa brings over 30 years of experience in the life sciences industry as an investor and an advisor, having guided public and private boards on strategic and financial transactions. He currently serves as a member of the Investment Advisory Committee and Advisory Board of One Ventures, an Australia-based venture capital firm; he also holds board positions with several biotechnology companies, including Neuron 23 Inc., DiCE Molecules, Blade Therapeutics, Inc., and Adverum Biotechnologies, Inc. Previously, Mr. Scopa served as a Managing Director of MPM Capital from May 2005 to June 2017; he spent the prior 15 years working at Deutsche Banc Alex. Brown and Thomas Weisel Partners, advising growth companies in biopharmaceuticals and medical devices. At Deutsche Banc Alex. Brown, Mr. Scopa served as Managing Director and Global Co-Head of Healthcare Investment Banking; at Thomas Weisel Partners, Mr. Scopa served on the Investment Committee for the company's health care venture fund as well as Co-Director of Healthcare Investment Banking.

Mr. Scopa added, "Aligos, with its esteemed management team and commitment to the utmost scientific rigor, has positioned itself to be a leader in chronic hepatitis B and other liver and viral diseases. I am privileged to help guide the company's vision with respect to clinical development as Aligos advances its programs."         

Mr. Scopa holds an A.B. from Harvard College, an M.B.A. from Harvard Business School and a J.D. from Harvard Law School.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos' clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos' ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos' capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos' Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 23, 2021 and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Media Contact

Amy Jobe, Ph.D.

LifeSci Communications

+1 315 879 8192

ajobe@lifescicomms.com

Investor Contact

Corey Davis, Ph.D.

LifeSci Advisors

+1 212 915 2577

cdavis@lifesciadvisors.com



Primary Logo

Get the next $ALGS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALGS

DatePrice TargetRatingAnalyst
8/19/2024$75.00Buy
H.C. Wainwright
1/6/2023$2.00 → $3.00Neutral → Overweight
Piper Sandler
1/6/2023$2.50 → $3.00Hold → Buy
Jefferies
3/23/2022$15.00 → $4.00Overweight → Neutral
Piper Sandler
3/11/2022$47.00 → $15.00Overweight
Piper Sandler
3/11/2022$10.00 → $11.00Outperform
SVB Leerink
2/16/2022$15.00 → $10.00Outperform
SVB Leerink
1/7/2022$30.00 → $12.00Overweight → Neutral
JP Morgan
More analyst ratings

$ALGS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Aligos Therapeutics Presents Positive Data at APASL 2025

    SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, being held March 26 - 30, 2025 in Beijing, China. "We are pleased to present preliminary data out to 96 weeks in our Phase 1 study of ALG-000184, which continues to demonstrate first-/best-in-class reductions in important HBV markers," stated Lawrence Blatt, PhD, MBA, Chairma

    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 4,000 shares of the Company's stock (the "Inducement Grant") to a newly hired employee on March 11, 2025 (the "Grant Date"), in connection with the commencement of employment. The Inducement Grant was granted pursuant to Aligos' 2024 Inducement Plan (the "Plan") as an inducemen

    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

    SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2024. "2024 was a pivotal year for the company, paving the way for the future of Aligos," stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "That future looks bright as we move ALG-000184 closer towards a Phase 2 clinical study, which is expected to begin in mid-2025. We continue to b

    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ALGS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ALGS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ALGS
SEC Filings

See more

$ALGS
Leadership Updates

Live Leadership Updates

See more
  • Aligos Therapeutics Appoints David Perry as Vice President of Business Development

    SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately. "We are pleased to welcome David to the Aligos team during this exciting time for the company," said Lesley Ann Calhoun, Executive Vice President and Chief Financial Officer at Aligos. "David's expertise in leading valuable partnerships will be instrumental as we strategically look to maximize the potential of our best-in-class pipeline

    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

    $ALGS
    $HAE
    $NVO
    $PLRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations
  • Aligos Therapeutics Strengthens Board with Two New Independent Directors

    SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", the "Company"))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointment of Heather Preston, M.D. and Margarita Chavez, J.D. as Class II Independent Directors to the Board of Directors, effective August 7, 2024. Dr. Preston will join the Nominating and Corporate Governance Committee as Chair and Ms. Chavez will join the Audit Committee. "We are pleased to announce the appointment of Dr. Heather Preston and Margarita Chavez to our Board of Directors," stated

    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ALGS
Financials

Live finance-specific insights

See more
  • Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

    ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat were up to 46.2% with a clear dose responseALG-055009 was well-tolerated with no serious adverse events or dose reductions. Importantly, ALG-055009 dose groups had a similar incidence of gastrointestinal-related adverse events with less diarrhea compared to placeboSignificant reductions in atherogenic lipids, including LDL-C, lipoprotein (a), and apolipoprotein B were observedConference call scheduled for 8:30am ET/5:30am PT today SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alig

    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

    SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company"))), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT. Conference Call & Webcast Details Th

    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

    CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolledsiRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studiesTHR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemiaMultiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvirMerck expanded the NASH research collaboration utilizing Aligos' proprietary oligonucleotide technology Cash, cash equivalents and investments of $205.8 million as of December 31, 2021 A sufficient

    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ALGS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more